The field of immunotherapy has long been dominated by the success of CAR T cell therapies, which have fundamentally changed the treatment landscape for blood based cancers. These treatments rely on modifying a patient’s T cells to recognize and attack malignant cells directly. Despite this success, solid tumors remain a significant challenge because they create a protective environment that actively suppresses immune responses.
While traditional dendritic cell vaccines were once viewed as a promising solution to this problem, they’ve largely struggled to produce consistent clinical results. The approval of Sipuleucel-T for prostate cancer in 2010 marked a milestone in the field, yet subsequent research showed that only a small fraction of patients achieved an objective immune response.
The failure of conventional dendritic cell vaccines is often attributed to the immunosuppressive factors present within the tumor microenvironment. These factors act as modulators that inhibit the very T cells the vaccine is trying to activate. To address these systemic limitations, a new patent from InmuCell Therapy US Inc proposes a shift in strategy. Instead of relying on the passive uptake of antigens by dendritic cells, the invention uses genetic engineering to equip these cells with chimeric antigen receptors, or CARs, to actively recognize tumor markers and reprogram the surrounding environment.
Engineering the Next Generation of Antigen Presenting Cells
Dendritic cells are the primary messengers of the immune system. Their natural role is to capture antigens, process them, and present them to T cells to initiate a targeted attack. The technical innovation described in US12569559B1 involves modifying these cells with a specific CAR architecture designed for the unique signaling requirements of a dendritic cell. Unlike a standard CAR T cell, which is built to kill, an engineered CAR dendritic cell is designed to activate and signal.
The structure of this chimeric receptor is divided into four primary components: an extracellular domain, a CD8a hinge domain, a CD8a transmembrane domain, and a specialized intracellular domain. The extracellular domain serves as the sensor, containing a guide sequence and a single chain antibody that allows the cell to recognize a specific tumor antigen. In the examples provided in the specification, the researchers utilized a receptor targeting the Epha2 antigen, which is frequently overexpressed in various cancers.
The most distinctive part of the engineering lies in the intracellular domain. The patent specifies a combination of the Dectin 1 intracellular domain and the intracellular domain of FcR gamma. This dual signaling approach is intended to transmit extracellular signals into the cell to activate internal pathways that are specific to dendritic cell function. By using these specific domains, the researchers aim to enhance the ability of the cells to acquire tumor antigens and present them to T cells, even in hostile environments.
Synergy Between Radiotherapy and Engineered Immunity
A critical aspect of the system described in the patent is the combined administration of the CAR modified cells with radiotherapy. The inventors suggest that radiotherapy provides a necessary foundation for the vaccine’s success by directly killing tumor cells and releasing a wave of antigens. This process creates a local inflammatory environment that increases the infiltration of immune cells.
The engineering details outlined in the patent describe a specific treatment timeline used in animal models. In one colorectal cancer study using MC38 cells, the treatment began with an intravenous injection of the CAR modified cells on the first day. This was followed by a 10 Gy dose of X ray irradiation on the second day, with a second infusion of cells occurring on the fourth day. A flow chart of this experimental process is illustrated in Figure 3 of the patent.
The results of these combined therapies were measured through tumor growth curves and weight analysis. As shown in Figure 4 and Figure 6, the combination of radiotherapy and CAR modified dendritic cells resulted in a significant inhibitory effect on tumor growth compared to the control groups. Statistical analysis of these results showed that the combined approach was more effective than either radiotherapy or cell therapy alone.
Reversing the Immunosuppressive Tumor Environment
The primary goal of this technology is to reverse the exhaustion of the immune system within a tumor. In the research presented, the inventors analyzed the phenotype of T cells that had successfully infiltrated the tumor after treatment. Using flow cytometry, as seen in Figure 7 and Figure 8, they found that the combination therapy significantly increased the presence of effector T cells.
Perhaps more importantly, the infiltrating T cells in the combination group exhibited lower levels of markers associated with immune exhaustion. Specifically, the researchers measured the expression of CTLA4 and PD1, which are proteins that tumors use to shut down immune attacks. The statistical charts in Figure 8 demonstrate that tumors treated with both CAR modified cells and radiation had a lower percentage of cells expressing these inhibitory markers compared to other groups.
This suggests that the engineered dendritic cells do more than just present antigens. They appear to modify the tumor microenvironment to make it more receptive to an immune response. By reducing the influence of immunosuppressive factors, the system allows the body’s natural T cells to function more effectively.
Technical Applications and Future Directions
The patent claims cover a wide range of source materials for these engineered cells. The dendritic cells can be derived from peripheral blood mononuclear cells, hematopoietic stem cells, or even induced pluripotent stem cells. The genetic material encoding the receptor can be delivered via DNA or mRNA using various vectors such as lentiviruses, plasmids, or liposomes.
The inventors also demonstrated the versatility of this approach across different types of cancer. In addition to the colorectal cancer models, the patent includes data from lung cancer (LLC) and breast cancer (4T1) studies in mice. In each case, the combination of the engineered cells and radiotherapy produced a significant reduction in tumor volume, which is documented in Figure 11 and Figure 16.
There is also a significant focus on human application. Example 5 of the patent describes the construction of humanized mice to test human Epha2 CAR proteins. In these models, which used human breast cancer cells (SKBR3), the treatment again showed a notable inhibitory effect on tumor growth, as visualized in the curves of Figure 18.
While the immediate application is focused on treating solid tumors that are currently difficult to manage, the broader implications of this work suggest a new category of tumor radiosensitizers. By using engineered immune cells to enhance the effects of traditional radiation, this technology provides a method for overcoming the biological defenses that tumors use to survive treatment. The work marks a transition from simple vaccines toward active, engineered systems that can remodel the immune landscape of a disease.
Exploring new approaches for cancer vaccines or immunotherapy development? Fill out the form to receive a customized patent insight brief on engineered cell therapies, combination treatments, and emerging oncology innovations.
